The Word 'Exosome' Has No Legal Definition on a European Skincare Label

Vogue España's pitch this week pairs retinol, the most studied anti-aging ingredient on the market, with exosomes, a term borrowed from cell biology that now sits on serum labels in Spain, the United States, China and South Korea. The pairing implies both ingredients answer to comparable oversight. They do not. Retinol carries decades of clinical trial data and, in several markets, a prescription-strength tier. Exosomes carry none of that, and the more specific fact is this: no cosmetics regulation in any of those four markets uses the word "exosome" to define what may or may not go into a jar.

That gap is worth tracing to its source, because it is not the same gap in every market, and the differences tell a shopper more than the ingredient list does.

What Spain's regulator actually told the people who asked

The Spanish Society of Aesthetic Medicine put the question to the Agencia Española de Medicamentos y Productos Sanitarios directly, and published the answer in its journal, Medicina Estética, around its 39th congress in Madrid in February 2024. The society's own account of that exchange, since cited by several Spanish aesthetic clinics, states plainly that exosomes "are not subject to specific restrictions in the annexes of Regulation 1223/2009," the law that governs cosmetic composition across the European Union. The AEMPS added a second, blunter point: no medicine authorized anywhere in Europe contains exosomes in its composition, of any origin. The only exosomes that may currently be injected in Spain are autologous ones, drawn from a patient's own cells, and even those, the clinics quoting AEMPS note, rest on thin published evidence. Everything else sold as an exosome product in Spain is, by the regulator's own classification, a cosmetic: something applied to the surface of healthy skin, not injected, not delivered past the epidermis, and not vetted as a medicine.

The one rule that comes close, and what it does not say

The AEMPS is not wrong that no line item names exosomes. Annex II of Regulation 1223/2009, the EU's list of substances banned outright from cosmetics, does contain an entry that a shopper might assume covers them: entry 416, which prohibits "cells, tissues or products of human origin." That wording is broad enough to reach human-derived exosomes without ever using the word, which is presumably why several cosmetics-compliance consultancies describe the EU as banning them by name when the text does not. What the entry does not touch is anything not of human origin, and that is the category almost every retail "exosome" serum actually falls into. Plant-, algae- and other non-animal-derived vesicles marketed under the same borrowed term face no exosome-specific EU rule at all. They are assessed the way any new cosmetic ingredient is assessed under the regulation: through a safety dossier the manufacturer itself compiles, with no additional review triggered by the word exosome on the label.

Put together, that means a serum bought in Madrid, Paris or Berlin advertising exosomes is almost certainly not carrying human cell material, since that is barred and, per the AEMPS, has never been the basis of an authorized medicine either. It is more likely carrying a vesicle from a plant, an alga or a bacterium, sold under a name that scientifically describes a much narrower category than the marketing suggests, and that has cleared no bar written with it in mind.

How three other markets draw a line the EU never drew

The United States is the most permissive of the four and has the most product volume to show for it. A compliance count of the US personal-care ingredient dictionary published by REACH24H found 28 distinct exosome-related ingredient names on file as of May 2025, sourced not only from plants but from human umbilical mesenchymal stem cells, deer amniotic fluid, salmon testis and milk. Human-derived exosomes can legally sit in an American cosmetic, because US law draws its line at the claim rather than the origin: a product that promises only to affect appearance stays a cosmetic, while one that promises to regenerate tissue or stimulate collagen production is reclassified as a drug requiring the trial data it does not have. The Food and Drug Administration's recent enforcement letters, sent through 2025 to clinics offering injectable exosome treatments, have targeted exactly that second category, medical claims made outside a drug approval, not shelf serums confining themselves to cosmetic language.

China occupies roughly the EU's position by a different route: its 2015 Safety and Technical Standards for Cosmetics bar human-derived exosomes outright, while non-human ones sit, as in Europe, outside any specific rule. China has since moved further than the EU has: in June 2025 its National Medical Products Administration folded extracellular vesicles, exosomes included, into the country's framework for advanced therapy medicinal products, a step toward treating the category as medicine rather than cosmetic ingredient, at least for some uses.

South Korea is the outlier, and the only one of the four with a rule that names the material specifically. Article 8 and Appendix 3 of the Cosmetics Act set safety standards written for human cell and tissue culture liquid, the regulatory category human-derived exosomes fall into there. Korea permits what the EU and China do not, but only after the material clears a standard built for it, rather than through the general cosmetic dossier process that governs everywhere else, including, for non-human exosomes, Korea itself.

What the word is actually certifying

Lined up, the four regimes do not converge on a shared definition of what an exosome is allowed to be in a beauty product. They converge on the opposite: each drew its line somewhere else, and only one of the four, South Korea, wrote a rule with the word in mind before products using it reached shelves. In Spain and the rest of the EU, the word functions as a scientific-sounding label pasted onto whatever species of extracellular vesicle a formulator sourced, evaluated under the same general safety process that governs a moisturizer's fragrance load.

None of that means the ingredient does nothing. Peer-reviewed human trials on topical, non-autologous exosome cosmetics remain few and mostly small, which is a separate, ongoing question from the regulatory one. What is established is narrower: the word on a Vogue España product recommendation, or on any serum next to it on a shelf, is not evidence that a regulator has looked at exosomes as a defined ingredient class and cleared them. In Spain specifically, the regulator has said the opposite, that no such review exists, and that the closest legal category the product could occupy is the one with the least scrutiny attached.

Sources: EUR-Lex, Regulation (EC) No 1223/2009 · AEMPS, cosmetics legislation